| Gene symbol | AFP | Synonyms | AFPD, FETA, HPAFP | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4q13.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | alpha fetoprotein | ||||
| GTO ID | GTC2416 |
| Trial ID | NCT04502082 |
| Disease | Hepatocellular Carcinoma |
| Altered gene | AFP |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | ET140203 TCR-T cells |
| HLA | HLA-A*02 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1) |
| Year | 2020 |
| Country | United States |
| Company sponsor | Eureka Therapeutics Inc. |
| Other ID(s) | ETUS19AFPAR121 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||